Shots:

• The company holds the inclusion and initiation of treatment in ongoing 3 studies i.e P-III in mastocytosis (AB15003)- P-III study in AML (AB19001) & P-II in COVID (AB20001) for masitinib- until the investigation of safety issue is completed
• The decision follows discussions with the French regulatory authorities (ANSM) and other regulatory agencies. The company also work closely with them to carry out the necessary additional analyzes
• AB Science has filed or will submit without delay a request for temporary discontinuation of the ongoing studies in all countries

  Ref: AB Science | Image: Twitter